Pharmacogenomics: Applications to Patient Care, third edition

Pharmacists and health care practitioners, educators, and trainees providing patient care services are affected by the ever-advancing science of pharmacogenomics. In re­sponse, ACCP’s third edition of Pharmacogenomics: Applications to Patient Care, developed by expert clinicians and researchers in the field, provides a state-of-the-art, clinically germane resource that distills the overwhelming body of scientific and clinical evidence and suggests practical actions for the translation and clinical ap­plication of pharmacogenetics to everyday practice.


Type Book
CME Available No
Topic
Cost $119.95
Note



Genomic Competencies

Experts from the disciplines listed below have tagged this resource as fulfulling genomic competencies.

Pharmacist

  • Basic Genetic Concepts
    • B1:   To demonstrate an understanding of the basic genetic/genomic concepts and nomenclature
    • B3:   To identify drug and disease associated genetic variations that facilitate development of prevention, diagnostic and treatment strategies and appreciate there are differences in testing methodologies and are aware of the need to explore these differences these differences in drug literature evaluation
  • Ethical, Legal and Social Implications (ELSI)
    • E1:   To understand the potential physical and/or psychosocial benefits, limitations and risk of genomic/pharmacogenomic information for individuals, family members and communities, especially with genomic/pharmacogenomic tests that may relate to predisposition to disease
    • E2:   To understand the increased liability that accompanies access to detailed genomic patient information and maintain confidentiality and security
    • E4:   To appreciate the cost, cost-effectiveness, and reimbursement by insurers relevant to genomic or pharmacogenomic tests and test interpretation, for patients and populations
  • Genetics and Disease
    • G1:   To understand the role of genetic factors in maintaining health and preventing disease
    • G2:   To assess the difference between clinical diagnosis of disease and identification of genetic predisposition to disease (genetic variation is not strictly correlated with disease manifestation)
    • G3:   To appreciate that pharmacogenomic testing may also reveal certain genetic disease predispositions (e.g. the Apo E4 polymorphism)
  • Pharmacogenetics/Pharmacogenomics
    • P1:   To demonstrate an understanding of how genetic variation in a large number of proteins, including drug transporters, drug metabolizing enzymes, direct protein targets of drugs, and other proteins (e.g. signal transduction proteins) influence pharmacokinetics and pharmacodynamics related to pharmacologic effect and drug response
    • P2:   To understand the influence (or lack thereof) of ethnicity in genetic polymorphisms and associations of polymorphisms with drug response